Blood-Based Biomarkers in the Diagnosis and Risk Stratification of Pancreatic Cysts. Gastrointest Endosc Clin N Am 2023 Jul;33(3):559-581
Date
05/29/2023Pubmed ID
37245936DOI
10.1016/j.giec.2023.03.009Scopus ID
2-s2.0-85153515158 (requires institutional sign-in at Scopus site)Abstract
The use of blood-based biomarkers for the assessment of pancreatic cystic lesions is a rapidly growing field with incredible potential. CA 19-9 remains the only blood-based marker in common use, while many novel biomarkers are in early stages of development and validation. We highlight current work in the fields of proteomics, metabolomics, cell-free DNA/circulating tumor DNA, extracellular vesicles, and microRNA among others, as well as barriers to development and future directions in the work of blood-based biomarkers for pancreatic cystic lesions.
Author List
Peller MT, Das KKAuthor
Matthew T. Peller MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
BiomarkersBiomarkers, Tumor
Carcinoma, Pancreatic Ductal
Humans
Pancreatic Cyst
Pancreatic Neoplasms
Risk Assessment
